Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3% – Still a Buy?

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) rose 6.3% during mid-day trading on Friday . The stock traded as high as $3.21 and last traded at $3.19. Approximately 1,267,020 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 2,772,484 shares. The stock had previously closed at $3.00.

Wall Street Analysts Forecast Growth

TSHA has been the topic of several recent research reports. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

The stock has a market capitalization of $664.01 million, a P/E ratio of 5.13 and a beta of 0.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The company’s fifty day simple moving average is $2.02 and its two-hundred day simple moving average is $2.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after acquiring an additional 682,273 shares during the period. State Street Corp grew its position in shares of Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares in the last quarter. Quantum Private Wealth LLC grew its position in shares of Taysha Gene Therapies by 5.1% during the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $931,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after purchasing an additional 33,123 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.